8-K: Cullinan Therapeutics Shares Promising Clinical Data for CLN-978 and Velinotamig

Cullinan Therapeutics announced updated clinical data for CLN-978 in rheumatoid arthritis and lupus, showing potential for remission, and initial data for velinotamig in lupus nephritis, demonstrating complete renal responses.

Summary

• Cullinan Therapeutics presented updated clinical data for CLN-978, a CD19xCD3 T cell engager, in patients with treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
• In the Phase 1 OUTRACE RA trial, multi-dose data showed robust efficacy, including clinical remission in one heavily pre-treated patient with a DAS28-ESR score reduction from 4.0 to 2.2, maintained through week eight.
• Safety data for the first three SLE patients treated with CLN-978 in the OUTRACE SLE trial were consistent with previously observed favorable safety profiles.
• Clinical observations in SLE patients with nephritis showed rapid improvement in proteinuria, supporting planned evaluation of CLN-978 in lupus nephritis with Phase 2a expansion expected in early 2027.
• Initial data from a Phase 1b/2a trial of velinotamig, a BCMAxCD3 T cell engager, in China showed promising clinical activity in treatment-refractory SLE patients, with both patients achieving complete renal response.
• SLEDAI-2K scores in velinotamig-treated patients decreased from baseline scores of 16 and 14 to 0 and 2, respectively, at week eight.
• Velinotamig demonstrated a favorable safety profile with no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome observed.
• Cullinan plans to initiate a Phase 1/2a trial for velinotamig in autoimmune cytopenias in Q1 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development due to the promising clinical data presented for both CLN-978 and velinotamig, indicating potential for significant therapeutic benefit in challenging autoimmune diseases.

Positives

• Updated Phase 1 data for CLN-978 in RA demonstrated robust efficacy, including clinical remission in a poly-refractory patient.
• CLN-978 treatment led to a rapid reduction in RA-associated autoantibodies.
• Safety data for CLN-978 in SLE patients were consistent with a favorable safety profile.
• Clinical observations in SLE patients with nephritis showed rapid improvement in proteinuria, supporting further development.
• Initial data for velinotamig in refractory SLE patients showed rapid and marked reductions in SLEDAI-2K scores.
• Both patients treated with velinotamig achieved complete renal response.
• Velinotamig demonstrated a favorable safety profile with no CRS or ICANS observed.
• The company has a defined path of multiple near-term catalysts anticipated for both programs.

Negatives

• The reported data for both CLN-978 and velinotamig are interim and subject to change as more data becomes available.
• There is no assurance that interim results will be predictive of final clinical trial outcomes.
• The company faces risks related to the success of clinical trials, regulatory submissions, and commercialization.

Risks

• Uncertainty regarding the timing and results of clinical trial data and regulatory submissions.
• Risk that regulatory submissions may not be cleared on expected timelines, or at all.
• The success of clinical trials and preclinical studies is not guaranteed.
• Risks related to protecting and maintaining the company's intellectual property position.
• Risks related to manufacturing, supply, and distribution of product candidates.
• The risk that product candidates may not be successfully developed and commercialized.
• The risk that preclinical or clinical trial results will not be predictive of future results.
• Risks associated with the success of collaboration, partnership, license, or similar agreements.

Future Outlook

Cullinan Therapeutics anticipates reporting additional multi-dose regimen data for CLN-978 in RA in the third quarter of 2026 and for SLE in the fourth quarter of 2026. Additional data for velinotamig is also expected in the fourth quarter of 2026. The company plans to initiate a Phase 1/2a clinical trial for velinotamig in autoimmune cytopenias in the first quarter of 2027, and a Phase 2a expansion for CLN-978 in lupus nephritis is expected to begin in early 2027.

Management Comments

• "We continue to build strong momentum across our T cell engager portfolio and are highly encouraged by the compelling data we have generated for our immunology programs, which demonstrate the broader potential of T cell engagers in autoimmune diseases."
• "Importantly, these data also support our strategy to develop differentiated CD19 and BCMA T cell engagers, designed to address the full spectrum of B cell and plasma celldriven autoimmune diseases."
• "For CLN-978, our OUTRACE SLE and RA clinical trials show that in heavily pretreated patients, all of whom discontinued background immunosuppressive therapies prior to study entry, CLN-978 achieved clinical remissions and deep B cell depletion, including indicators of immune reset."
• "These data support the potential for CLN-978 to deliver durable, treatment-free remissions in the community out-patient setting, representing a meaningful shift in how these diseases may be managed."
• "With our global clinical footprint, we are prepared to advance quickly into the next phase of development, including planned indication expansion."
• "In parallel, velinotamig has demonstrated promising early clinical efficacy, including complete renal responses, with pharmacodynamic effects aligned with its mechanism."
• "Based on these initial observations, we are focused on expanding the current dataset and advancing into additional autoantibody-mediated conditions with high unmet need."
• "Looking ahead, we have a defined path of multiple near-term catalysts anticipated for both programs, with additional multi-dose data for CLN-978 in RA next quarter and in SLE in Q4, and additional data for velinotamig before the end of the year."

Industry Context

StockSavvy.ai notes that Cullinan Therapeutics' announcement highlights the growing application of T cell engager technology, traditionally used in oncology, to treat complex autoimmune diseases. The company's focus on both CD19 and BCMA targets suggests a strategy to address a broad range of B cell and plasma cell-driven conditions, aligning with industry trends towards targeted immunotherapies for autoimmune disorders.

Comparison to Industry Standards

• The reported DAS28-ESR remission in a rheumatoid arthritis patient (reduction from 4.0 to 2.2) is a significant positive outcome, indicating a strong therapeutic effect in a heavily pre-treated patient.
• The achievement of complete renal response in two patients with refractory SLE treated with velinotamig is a notable success, as lupus nephritis has a historically high mortality rate.
• The reduction in SLEDAI-2K scores from 16 and 14 to 0 and 2, respectively, demonstrates substantial disease control, which is a key benchmark in SLE treatment.
• The favorable safety profile observed for both CLN-978 and velinotamig, particularly the absence of CRS and ICANS with velinotamig, is critical for advancing these therapies, as these are known risks with T cell engagers.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical data, potentially increasing the perceived value of the company and its pipeline.
• Patients: Potential for new, effective treatment options for rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and autoimmune cytopenias, addressing significant unmet medical needs.
• Healthcare Providers: Introduction of novel T cell engager therapies could offer new treatment paradigms for complex autoimmune diseases.

Next Steps

• Report additional multi-dose regimen data for CLN-978 in RA in Q3 2026.
• Report additional multi-dose regimen data for CLN-978 in SLE in Q4 2026.
• Share additional multi-dose regimen data for velinotamig in patients with SLE from the Genrix clinical trial in China in Q4 2026.
• Initiate a Phase 1/2a clinical trial for velinotamig in patients with autoimmune cytopenias in Q1 2027.
• Begin Phase 2a expansion of CLN-978 in patients with lupus nephritis in early 2027.

Key Dates

Recommendation

The presented data is encouraging, showing positive efficacy and safety signals for both CLN-978 and velinotamig. However, the results are interim and from early-stage trials. While promising, further data and progression through later-stage trials are needed to confirm efficacy and safety before a stronger recommendation can be made. Therefore, a 'hold' position is appropriate, awaiting more definitive clinical evidence.

Keywords

Cullinan Therapeutics, CLN-978, Velinotamig, T cell engager, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases